Tags

Type your tag names separated by a space and hit enter

Safety and length of benefit of restylane for office-based injection medialization-a retrospective review of one institution's experience.
J Voice. 2014 Sep; 28(5):631-5.JV

Abstract

OBJECTS

Restylane is a relatively new material being used for temporary vocal fold medialization. Few studies have evaluated the safety, complication rate, and length of benefit derived from Restylane injection medialization. We report on 64 patients who underwent office-based injection medialization with Restylane to establish the safety of and length of benefit from this material.

STUDY DESIGN

Retrospective review.

METHODS

Retrospective review of patients who underwent office-based injection medialization with Restylane during a 2-year period was performed.

RESULTS

Eighty-two injections in 64 patients were reviewed. Five total adverse events occurred (3.88%). The average length of benefit from injection medialization with Restylane was 12.2 weeks. No inflammatory or hypersensitivity reactions to Restylane occurred. A trend toward avoidance of permanent medialization was observed in patients injected <6 months from time of injury compared with patients injected >6 months after (P = 0.0511).

CONCLUSION

Restylane is a safe and effective temporary material for office-based injection medialization with an average length of benefit of 12.2 weeks. This represents the largest series to date using Restylane and no hypersensitivity or granulomatous reactions were observed. Our data showed a trend toward avoidance of permanent medialization in patients who were injected <6 months after nerve injury, which supports the findings of others.

Authors+Show Affiliations

Cleveland Clinic Foundation, Head and Neck Institute, Cleveland, Ohio.Cleveland Clinic Foundation, Head and Neck Institute, Cleveland, Ohio. Electronic address: brysonp@ccf.org.Cleveland Clinic Foundation, Head and Neck Institute, Cleveland, Ohio.Cleveland Clinic Foundation, Head and Neck Institute, Cleveland, Ohio.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

24529939

Citation

Halderman, Ashleigh A., et al. "Safety and Length of Benefit of Restylane for Office-based Injection Medialization-a Retrospective Review of One Institution's Experience." Journal of Voice : Official Journal of the Voice Foundation, vol. 28, no. 5, 2014, pp. 631-5.
Halderman AA, Bryson PC, Benninger MS, et al. Safety and length of benefit of restylane for office-based injection medialization-a retrospective review of one institution's experience. J Voice. 2014;28(5):631-5.
Halderman, A. A., Bryson, P. C., Benninger, M. S., & Chota, R. (2014). Safety and length of benefit of restylane for office-based injection medialization-a retrospective review of one institution's experience. Journal of Voice : Official Journal of the Voice Foundation, 28(5), 631-5. https://doi.org/10.1016/j.jvoice.2014.01.010
Halderman AA, et al. Safety and Length of Benefit of Restylane for Office-based Injection Medialization-a Retrospective Review of One Institution's Experience. J Voice. 2014;28(5):631-5. PubMed PMID: 24529939.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and length of benefit of restylane for office-based injection medialization-a retrospective review of one institution's experience. AU - Halderman,Ashleigh A, AU - Bryson,Paul C, AU - Benninger,Michael S, AU - Chota,Rebecca, Y1 - 2014/02/13/ PY - 2013/10/28/received PY - 2014/01/15/accepted PY - 2014/2/18/entrez PY - 2014/2/18/pubmed PY - 2015/5/20/medline KW - Hyaluronic acid KW - Injection laryngoplasty KW - Laryngology KW - Videostroboscopy SP - 631 EP - 5 JF - Journal of voice : official journal of the Voice Foundation JO - J Voice VL - 28 IS - 5 N2 - OBJECTS: Restylane is a relatively new material being used for temporary vocal fold medialization. Few studies have evaluated the safety, complication rate, and length of benefit derived from Restylane injection medialization. We report on 64 patients who underwent office-based injection medialization with Restylane to establish the safety of and length of benefit from this material. STUDY DESIGN: Retrospective review. METHODS: Retrospective review of patients who underwent office-based injection medialization with Restylane during a 2-year period was performed. RESULTS: Eighty-two injections in 64 patients were reviewed. Five total adverse events occurred (3.88%). The average length of benefit from injection medialization with Restylane was 12.2 weeks. No inflammatory or hypersensitivity reactions to Restylane occurred. A trend toward avoidance of permanent medialization was observed in patients injected <6 months from time of injury compared with patients injected >6 months after (P = 0.0511). CONCLUSION: Restylane is a safe and effective temporary material for office-based injection medialization with an average length of benefit of 12.2 weeks. This represents the largest series to date using Restylane and no hypersensitivity or granulomatous reactions were observed. Our data showed a trend toward avoidance of permanent medialization in patients who were injected <6 months after nerve injury, which supports the findings of others. SN - 1873-4588 UR - https://www.unboundmedicine.com/medline/citation/24529939/Safety_and_length_of_benefit_of_restylane_for_office_based_injection_medialization_a_retrospective_review_of_one_institution's_experience_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0892-1997(14)00011-3 DB - PRIME DP - Unbound Medicine ER -